Axsome Therapeutics, Inc. (AXSM)

Market Cap	5.50B
Revenue (ttm)	432.16M
Net Income (ttm)	-278.27M
Shares Out	49.38M
EPS (ttm)	-5.77
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	524,015
Open	110.11
Previous Close	110.12
Day's Range	109.81 - 112.62
52-Week Range	72.21 - 139.13
Beta	0.46
Analysts	Strong Buy
Price Target	171.65 (+54.2%)
Earnings Date	Aug 4, 2025

About AXSM

Axsome Therapeutics, Inc., a biopharmaceutical company, develops and delivers novel therapies for the management of central nervous system (CNS) disorders in the United States. The company’s commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist, sigma-1 receptor agonist, aminoketone, and CYP2D6 inhibitor indicated for the treatment of major depressive disorder in adults; Sunosi (solriamfetol), a dopamine and norepinephrine reuptake inhibitor, trace amine-associated receptor 1 ago...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Nov 19, 2015
• Employees: 683
• Stock Exchange: NASDAQ
• Ticker Symbol: AXSM
• Website: https://www.axsome.com

Financial Performance

In 2024, Axsome Therapeutics's revenue was $385.69 million, an increase of 42.53% compared to the previous year's $270.60 million. Losses were -$287.22 million, 20.1% more than in 2023.

Analyst Summary

According to 17 analysts, the average rating for AXSM stock is "Strong Buy." The 12-month stock price target is $171.65, which is an increase of 54.20% from the latest price.

Price Target

$171.65

(54.20% upside)

Analyst Consensus: Strong Buy